A woman gives birth in a hospital in Kenya, Nigeria, South Africa or Tanzania. The baby is healthy. Over the next hour, she keeps bleeding. Not dramatically, not enough for anyone to panic. The midwife glances at the sheets and judges it within normal range.
It isn’t. By the time the bleeding is obvious, it is dangerous.
Postpartum haemorrhage is the leading cause of maternal death worldwide. And one of the most important trials in maternal health in years showed that a large part of the problem was not a lack of drugs or skill. It was that clinicians could not see how much blood was being lost.
A 60% reduction from measuring properly
The E-MOTIVE trial, published in the New England Journal of Medicine in 2023, randomised 80 secondary-level hospitals across Kenya, Nigeria, South Africa and Tanzania. More than 210,000 women who gave birth vaginally were included.
The intervention had two parts. First, a calibrated plastic drape placed under the woman after birth to collect and measure blood loss objectively. Second, a bundle of treatments given together as soon as haemorrhage was detected: uterine massage, drugs to contract the uterus, tranexamic acid, intravenous fluids, and examination with escalation if bleeding continued.
The results were striking. In usual-care hospitals, postpartum haemorrhage was detected in 51% of women who had it. With the drape, detection rose to 93%. Use of the full treatment bundle rose from 19% to 91%. The primary outcome, a combination of severe haemorrhage, surgery for haemorrhage or death from it, fell from 4.3% to 1.6%, a 60% reduction in risk.
None of the treatments in the bundle was new. What changed was that staff knew, early and with confidence, that they needed to act.
Why this matters more than it sounds
The global picture explains why an intervention like this deserves attention. According to the UN inter-agency estimates released in 2025, around 260,000 women died from pregnancy and childbirth-related causes in 2023. That was a 40% fall since 2000, but progress has slowed sharply: since 2016, the global maternal mortality ratio has fallen by only about 1.5% a year. Sub-Saharan Africa accounted for about 70% of maternal deaths.
For years, maternal health policy has emphasised getting women to give birth in facilities with skilled attendants. That was the right priority, and it helped drive the gains of the early 2000s. But the stall since 2016 suggests that getting women through the door is no longer enough. The quality of what happens inside the facility now decides a large share of outcomes.
E-MOTIVE is a quality intervention. It doesn’t bring anyone new into the hospital. It changes what happens once they are there.
The pattern repeats: cheap tools, slow adoption
This is not the first time a simple intervention has shown dramatic results in maternal health.
In 2002, the Magpie trial, published in The Lancet, enrolled more than 10,000 women with pre-eclampsia in 33 countries. Women given magnesium sulphate had a 58% lower risk of eclampsia than those given placebo. Magnesium sulphate is inexpensive and has been recommended by WHO for years.
But a recommendation is not the same as a drug in the right place, at the right moment. For many proven maternal interventions, the problem is rarely the evidence or even the price. It is the system around the drug: whether it is stocked, whether staff are trained and confident to use it, whether there are protocols and someone to check they are followed.
The uncomfortable incentive
Maternal health funding has tended to favour things that can be counted easily: facility births, antenatal visits, numbers of trained midwives. Those are useful measures. But they reward access, not quality.
A hospital can post excellent numbers on facility births while its staff eyeball blood loss, its oxytocin sits in a warm storeroom losing potency, and its escalation protocol lives in a binder no one opens. The metrics look good. The outcomes don’t move.
Interventions like E-MOTIVE are hard to fund under that logic because their value only shows up in outcomes, not in activity counts. They also lack a champion. A calibrated drape has no software to license and no platform to sell, so nobody is paid to push it into every labour ward.
What should get priority
If the goal is the biggest reduction in maternal deaths for the money, the evidence points to a consistent set of priorities:
- Measure blood loss objectively. Visual estimation misses haemorrhage too often. A calibrated drape is cheap.
- Treat in bundles, early. Giving treatments together as soon as haemorrhage is detected beats escalating one step at a time.
- Keep the basics stocked and effective. Magnesium sulphate, tranexamic acid and uterotonics are only useful if they’re available and stored correctly.
- Pay for quality, not just attendance. Funding should follow outcomes such as haemorrhage detected and treated, not just births counted.
Why eyeballing fails
It is worth pausing on why clinicians miss haemorrhage so often, because the reason is not carelessness.
Blood after birth is mixed with amniotic fluid and soaks into sheets, pads and the mattress. Some pools out of sight. Loss often happens gradually, over an hour, rather than in one visible gush. A midwife caring for several women at once sees each of them intermittently. Young, healthy women can compensate for significant blood loss for some time, keeping their pulse and blood pressure near normal until they suddenly deteriorate.
All of this makes visual estimation unreliable, and the E-MOTIVE data show how unreliable. In usual-care hospitals, only about half of haemorrhages were detected. That is not a failure of individual clinicians. It is a failure of a method.
The calibrated drape replaces a judgement with a measurement. It collects blood in a marked pouch, so that when loss crosses a threshold, it is visible to everyone in the room. It also creates a shared fact. A midwife who sees the line crossed doesn’t have to persuade a doctor that the bleeding is serious. The drape shows it.
That shared fact is what makes the bundle possible. Once haemorrhage is detected objectively, the team doesn’t debate. It acts, and it acts with several treatments at once, rather than trying one, waiting, and escalating.
A worked example: the night shift
Imagine a busy labour ward at 2 a.m. There are two midwives for a dozen women in various stages of labour and recovery. One woman delivered forty minutes ago and seems fine.
In the usual-care version, a midwife checks on her between other tasks. The pad looks heavy but not alarming. She massages the uterus and makes a note to check again. When she returns, the woman is pale and her pulse has climbed. Now there is a scramble: oxytocin, a call to the doctor, an intravenous line. The doctor arrives, orders more drugs, and considers theatre. Each step is taken in sequence, and each takes time.
In the E-MOTIVE version, a drape was placed under the woman at birth. When the midwife checks, the blood has reached the line. There is no discussion. The midwife starts the bundle: uterine massage, a uterotonic drug, tranexamic acid, intravenous fluids, and an examination for the cause of bleeding. The doctor is called because the protocol requires it, not because the midwife had to make a case.
The drugs, the staff and the ward are the same. What differs is timing, and in haemorrhage, timing is most of what matters.
The strongest counterargument
The strongest objection is that a trial result, however striking, may not survive routine implementation.
E-MOTIVE involved training, champions, audit and feedback, and implementation support. In ordinary conditions, with staff turnover, drape stock-outs and competing priorities, effects may shrink. Some critics would add that the biggest drivers of maternal death in the poorest settings are structural: women who can’t reach a facility at all, facilities without blood for transfusion, and referral systems that don’t function. A drape does nothing for a woman who gives birth at home or in a clinic without drugs.
This argument partly holds. The trial’s implementation strategies were part of the intervention, and scaling them requires investment. And E-MOTIVE is a facility-based intervention; it doesn’t solve access.
But it would be a mistake to let the size of the structural problem justify inaction on the solvable part. Many births in the countries with the highest maternal mortality already happen in facilities. For the women giving birth in those facilities, the difference between detecting haemorrhage in half of cases and in nearly all is enormous. The honest position is that E-MOTIVE is not the whole answer to maternal mortality. It is one of the most effective answers tested so far for the women who are already inside the building.
Second-order effects
Measurement changes culture. When blood loss is measured, teams begin to talk about it in numbers, which makes audit, feedback and learning easier. Objective measurement can shift a ward from reacting to crises to managing risk.
Supply chains become clinical. The bundle depends on uterotonics, tranexamic acid and fluids being available and effective. Some uterotonics lose potency without proper storage. A detection programme will expose supply failures that were previously hidden, which is uncomfortable but useful.
Midwives gain authority. A protocol that allows midwives to start treatment on the basis of a measurement, without waiting for a doctor, can change the balance of decision-making on a labour ward. That is good for speed but requires training and clear responsibility.
Measuring what matters
The final lesson from E-MOTIVE is about what health systems choose to measure. For years, the core indicators for maternal care focused on whether women reached facilities and whether a skilled attendant was present. Those indicators said little about whether bleeding was detected in time, or whether the right drugs were given together.
A system that tracks the proportion of haemorrhages detected by objective measurement, and the proportion treated with the full bundle within a set time, can see where care breaks down. Those are simple numbers to collect when a drape is in use. They are also the numbers most closely connected to whether women survive.
What this means for decision-makers
For ministries of health, it means adopting objective blood-loss measurement and bundled treatment as standard care in facilities, and funding the drapes, drugs and training as a package.
For hospital managers, it means ensuring that every birth has a drape, every ward has the bundle drugs stored correctly, and every shift knows the protocol.
For funders, it means paying for implementation, not just commodities, and measuring success by haemorrhage detected and treated.
For midwives and obstetricians, it means trusting the measurement over the eye, and acting on it without delay.
What to watch next
Watch how quickly countries incorporate E-MOTIVE’s approach into national guidelines and training, and whether real-world programmes report detection and bundle-use rates similar to the trial. Watch the next UN maternal mortality estimates for signs that the stall since 2016 is breaking. And watch whether funding cuts to global health reverse the gains already made.
The takeaway
The most powerful maternal health intervention in recent years did not involve a new drug, a new facility or a new cadre of health workers. It involved measuring something that had been guessed at, and acting on the result without delay.
Maternal deaths have stalled not because we don’t know what works. They have stalled because the systems that deliver it still guess when they should measure.
Which proven maternal health intervention is most under-used where you work, and why? Share your experience below.
